Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2014/061012external-prioritypatent/WO2014177982A1/en
Application filed by Glaxosmithkline Ip No 2 LtdfiledCriticalGlaxosmithkline Ip No 2 Ltd
Publication of CR20150593ApublicationCriticalpatent/CR20150593A/en
Esta invención se refiere a compuestos novedosos de acuerdo con la Fórmula (I) que son inhibidores del Potenciador de Homólogo Zeste 2 (EZH2), a composiciones farmacéuticas que los contienen, a procedimientos para su preparación y a su uso en terapia para 5 el tratamiento de cánceres.This invention relates to novel compounds according to Formula (I) that are inhibitors of the Zeste 2 Homologous Enhancer (EZH2), to pharmaceutical compositions containing them, to methods for their preparation and their use in therapy for the treatment of cancers
CR20150593A2013-04-302015-10-30
POTENTIAL OF INHIBITORS OF THE HOMOLOGIST OF ZESTE
CR20150593A
(en)
Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.